Symbiotec Pharmalab IPO Lists at 1% Discount on BSE, Flat on NSE

Symbiotec Pharmalab shares made a muted stock market debut on Tuesday, 1 September 2026. The stock listed at ₹978.20 per share on the BSE, representing a discount of around 1% to its IPO issue price of ₹988. On the NSE, the shares debuted flat at ₹988.

Following the listing, Symbiotec Pharmalab shares witnessed sharp volatility. On the BSE, the stock touched an intraday high of ₹1,120 and a low of ₹933.80. On the NSE, shares climbed to ₹1,124.50 before falling to a low of ₹934.20.

The listing came amid weak broader market sentiment, with benchmark indices Sensex and Nifty 50 declining by up to 0.30% during morning trade.

The listing followed an IPO that witnessed strong investor participation, with the issue subscribed around 75 times overall.

Symbiotec Pharmalab IPO Listing Details

Symbiotec Pharmalab launched its IPO as a book-built public issue comprising a fresh issue and an offer for sale (OFS). The IPO opened for subscription on 24 August and closed on 27 August 2026. Share allotment was finalised on 28 August, while the shares were listed on the NSE and BSE on 1 September 2026.

The IPO comprised a fresh issue of 15.21 lakh shares aggregating to ₹150 crore and an OFS of 1.63 crore shares aggregating to ₹1,607 crore.

The public issue received an overall subscription of around 75 times.

• Issue Price: ₹988 per share
• NSE Listing Price: ₹988 per share
• NSE Listing Performance: Flat
• BSE Listing Price: ₹978.20 per share
• BSE Listing Discount: Around 1%
• NSE Intraday High: ₹1,124.50
• NSE Intraday Low: ₹934.20
• BSE Intraday High: ₹1,120
• BSE Intraday Low: ₹933.80
• Overall Subscription: Around 75 times

First-Day Trading Performance

Listing Price: Symbiotec Pharmalab share price debuted at ₹978.20 per share on the BSE against its IPO issue price of ₹988, translating into a listing discount of around 1%. On the NSE, the stock made a flat debut at ₹988 per share.

Following the muted listing, the stock witnessed significant volatility on both exchanges. On the BSE, Symbiotec Pharmalab shares climbed to an intraday high of ₹1,120, approximately 13.36% above the issue price, before falling to a low of ₹933.80.

On the NSE, the stock touched an intraday high of ₹1,124.50, around 13.82% above the IPO price, before declining to ₹934.20.

The volatile first-day trading came amid weakness in the broader equity market, with the Sensex and Nifty 50 declining by up to 0.30% during morning deals.

The listing followed strong demand for the IPO, which was subscribed around 75 times overall.

Growth Drivers and Challenges

Growth Drivers

Diversified Product Portfolio: Symbiotec Pharmalab manufactures APIs, nutritional ingredients and speciality pharmaceutical products.

Domestic and International Markets: The company serves customers across domestic, regulated and emerging international markets.

Revenue Growth: Revenue from operations increased from ₹716.25 crore in FY24 to ₹869.15 crore in FY26.

Pharmaceutical Manufacturing Exposure: The business participates in pharmaceutical and biotechnology manufacturing segments.

Established API Operations: Active pharmaceutical ingredients form an important part of the company's product portfolio.

Challenges

Profit Fluctuations: Profit declined in FY25 before recovering during FY26.

Regulatory Requirements: Pharmaceutical manufacturing operations remain subject to stringent regulatory and quality requirements.

International Market Exposure: Overseas operations can expose the business to changing regulatory and market conditions.

Competitive Pharmaceutical Industry: The company operates in a competitive pharmaceutical and API manufacturing market.

Post-Listing Volatility: The stock witnessed a wide trading range during its first session on the exchanges.

Utilisation of IPO Proceeds

Symbiotec Pharmalab plans to utilise the proceeds from the fresh issue primarily towards:

• Repayment of certain loans
• General corporate purposes

The IPO comprised a fresh issue of 15.21 lakh shares aggregating to ₹150 crore and an offer for sale of 1.63 crore shares aggregating to ₹1,607 crore.

The fresh issue proceeds of ₹150 crore are intended primarily for debt repayment and general corporate requirements.

Business and IPO Overview

Symbiotec Pharmalab is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and speciality products.

The company caters to domestic and international markets, including regulated and emerging regions.

Symbiotec Pharmalab reported revenue from operations of ₹716.25 crore in FY24, which increased to ₹751.55 crore in FY25 and ₹869.15 crore in FY26.

Profit attributable to owners of the parent company stood at ₹100.18 crore in FY24, declined to ₹96.78 crore in FY25 and subsequently increased to ₹109.88 crore in FY26.

The company entered the public markets through a book-built IPO comprising a fresh issue of 15.21 lakh shares aggregating to ₹150 crore and an OFS of 1.63 crore shares aggregating to ₹1,607 crore. The IPO was subscribed around 75 times overall.

Symbiotec Pharmalab made its stock market debut on 1 September 2026, listing at ₹978.20 on the BSE, around 1% below its issue price of ₹988, while the stock debuted flat at ₹988 on the NSE.

Following the listing, shares witnessed significant volatility. The stock touched highs of ₹1,120 on the BSE and ₹1,124.50 on the NSE, while intraday lows stood at ₹933.80 and ₹934.20, respectively.